However, it is notable that in the AML setting CD33 has been recently tested as target for preclinical validation of a novel strategy with CAR engineered CIK cells as a means of adoptive immunotherapy (97).CIK cells have been transduced with a CD33.CAR by using a non-viral system, which offers improved transfection efficiency. The gene discussed is CD33; the disease is acute myeloid leukemia.